2,2-dimethyl-6-[(4,6-diphenyl-pyridin-2-yl)oxy]hexanonitrile | 141747-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,2-dimethyl-6-[(4,6-diphenyl-pyridin-2-yl)oxy]hexanonitrile
• 英文别名: 2,2-dimethyl-6-<(4,6-diphenyl-2-pyridyl)oxy>hexanenitrile；6-[(4,6-diphenyl-2-pyridinyl)oxy]-2,2-dimethylhexanenitrile；2,2-dimethyl-6-[(4,6-diphenyl-2-pyridyl)oxy]hexanonitrile；6-(4,6-diphenylpyridin-2-yl)oxy-2,2-dimethylhexanenitrile
• CAS: 141747-91-3
• 化学式: C₂₅H₂₆N₂O
• 分子量: 370.494
• InChiKey: YOEOOKFQJWVJPF-UHFFFAOYSA-N

物化性质

• 沸点：
  532.0±50.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-6-[(4,6-diphenyl-pyridin-2-yl)oxy]hexanonitrile 在 sodium tetrahydroborate 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-amino-3-(N-(6-(4,6-diphenyl(2-pyridyloxy))-2,2-dimethylhexyl)carbamoyl)propanoic Acid (Trifluoroacetic Acid Salt)
  参考文献：
  名称：

  LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation

  摘要：

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备放射性药物的试剂和试剂盒，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位积聚的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。

  公开号：

  EP1293214A3
• 作为产物：
  描述：

  4,6-二苯基-2(1H)-吡啶酮 、 6-溴-2,2-二甲基己腈 在 silver carbonate silica gel 作用下， 以 甲苯 为溶剂， 生成 2,2-dimethyl-6-[(4,6-diphenyl-pyridin-2-yl)oxy]hexanonitrile
  参考文献：
  名称：

  Substituted quinolyl compounds exhibiting selective leukotriene B.sub.4

  摘要：

  本发明涉及具有选择性LTB.sub.4拮抗剂特性的化合物。包括该化合物的治疗组合物和使用该组合物治疗涉及LTB.sub.4激动剂介导的活性的疾病的方法，其中该化合物由以下式子描述：##STR1## 其中R.sub.4、X、R、Y、R'、Q、m和n在此定义，并且其药学上可接受的盐。

  公开号：

  US05492915A1

文献信息

• Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
  申请人：——

  公开号：US20030003049A1

  公开（公告）日：2003-01-02

  The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.

  本发明提供了包括放射标记的LTB4结合剂和放射标记的灌注成像剂的新型诊断组合物，包括这种组合物的诊断试剂盒，以及在哺乳动物中进行同时成像的方法，包括给予放射标记的LTB4结合剂和放射标记的灌注成像剂，并同时检测结合在LTB4受体上的放射标记的LTB4结合剂和放射标记的灌注成像剂。
• Radiopharmaceuticals for imaging infection and inflammation
  申请人：——

  公开号：US20030124053A1

  公开（公告）日：2003-07-03

  The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备这些放射性药物的试剂和工具包，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位聚集的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05366982A1

  公开（公告）日：1994-11-22

  This invention relates to compounds having selective LTB.sub.4 antagonist properties, compositions comprising said compounds and methods for the treatment of disorders involving LTB.sub.4 agonist-mediated activity utilizing said compositions wherein the compounds are described by the general formula ##STR1## and pharmaceutically acceptable salts thereof.

  本发明涉及具有选择性LTB.sub.4拮抗性的化合物，包括所述化合物的组合物以及利用所述组合物治疗涉及LTB.sub.4激动剂介导活性的疾病的方法，其中所述化合物由一般公式##STR1##和其药用可接受的盐描述。
• .omega.-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists
  作者：Richard Labaudiniere、Norbert Dereu、Francoise Cavy、Marie Christine Guillet、Olivier Marquis、Bernard Terlain

  DOI：10.1021/jm00101a008

  日期：1992.11

  A series of omega-[(4,6-diphenyl-2-pyridyl)oxy]alkanoic acid derivatives was prepared which inhibited the binding of leukotriene B4 to its receptors on guinea pig spleen membranes and on human polymorphonuclear leukocytes (PMNs) and selectively antagonized the LTB4-induced elastase release in human PMNs. On the basis of these three screens, a structure-activity relationship was investigated. Alpha-Substitution on the carboxylic acid side chain led to only small changes in the binding affinities but greatly enhanced the LTB4 antagonist activity. Substitution on the phenyl rings was also evaluated. The terminal carboxylic acid function can be replaced by a tetrazole ring without loss in activity. The beat in vitro LTB4 antagonists of this series were investigated in vivo in the inhibition of LTB4-induced leukopenia in rabbits. Compound 9b (RP69698) displayed potent LTB4 antagonist activity, after oral administration, with an ED50 value of 6.7 mg/kg.
• Labaudiniere Richard, Dereu Norbert, Cavy Francoise, Guillet Marie-Christ+, J. Med. Chem., 35 (1992) N 23, S 4315-4324
  作者：Labaudiniere Richard, Dereu Norbert, Cavy Francoise, Guillet Marie-Christ+

  DOI：——

  日期：——